We advised the sales agent on the offering

Davis Polk advised the sales agent in connection with the SEC-registered at-the-market offering by Maze Therapeutics, Inc. of its common stock for up to an aggregate amount of $200 million. The common stock is listed on the Nasdaq Global Market under the symbol “MAZE.”

Maze Therapeutics is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with kidney and metabolic diseases, including obesity.

The Davis Polk corporate team included partner Emily Roberts and associates Rebecca Lei and Matthew Kenney. Partner David R. Bauer and associate Jordan Khorshad provided intellectual property advice. Counsel Dustin Plotnick and associate Carter Ballentine Allison provided tax advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California and New York offices

Copy link to share post